Our Mission
Vision Mission Values
Our vision is to be recognised by our clients as the most knowledgeable and reliable partner in providing value-added consultancy services throughout our organisation.
Our mission is to deliver value and sustainable knowledge for successful market entry and strong market growth to our clients in the pharmaceutical, medical device and biotech sectors. We respect ethical principles accelerating patients’ access to better treatments while delivering a fair added value to our clients.
Values
Integrity - We advise our clients thus their business can obtain a smooth market entry and achieve their growth potential. We believe that we will perfectly indentify your needs and deliver the required tailored solutions. We propose the most efficient working framework and charge a fair fee to complete the work.
Responsibility – Fully aware that our valued clients invest their trust in us, we guide them through complicated regulatory processes and, where required, represent them towards authorities, regulatory bodies, etc. We are ready to successfully assist companies to negotiate their way through the market access hurdles such as reimbursement, regulatory and other processes, to deliver value and results.
About
TESTIMONIALS
“With their depth of market access experience across the EU, Adam Barak and his team at PPi Healthcare are well-positioned to provide timely, insightful guidance on pricing and reimbursement. ProMetic’s global strategic launch plans involving ultra-orphan therapies, have been greatly enhanced by our collaboration with PPi.”
Kristine Dorward, Director, Marketing & Business Development, ProMetic Life Sciences Inc.
“I want to let you know that the feedback from my colleagues after your presentation was that they are impressed by the amount of information that you have gathered within the research within such a short period.”
Ramona Schmid, Global Market Access, Pricing and Reimbursement Manager, HRA Pharma
“I have worked with PPi on several projects and I will work with them again. The first project was a European pricing study for an orphan product. Having already completed one study with a competitor, I found the PPi team to be particularly insightful, having taken the time to completely understand this complex project.”
Thomas W. MacAllister JD, PhD, Vice President of R&D and General Counsel, Remedy Pharmaceuticals
“Recently I completed an assessment to inform the collection of pharmacoeconomic data in a clinical study in the US and Europe. The team again were very insightful and we had unexpected value-added when we found a member of the PPi had been involved in the pricing and reimbursement activities relating to one of our comparables. Great team, great results!”
Thomas W. MacAllister JD, PhD, Vice President of R&D and General Counsel, Remedy Pharmaceuticals
